Artisan Partners Limited Partnership Raises Stock Position in Stevanato Group S.p.A. (NYSE:STVN)

Artisan Partners Limited Partnership boosted its position in shares of Stevanato Group S.p.A. (NYSE:STVN) by 28.7% in the fourth quarter, HoldingsChannel reports. The fund owned 2,355,799 shares of the company’s stock after purchasing an additional 524,989 shares during the quarter. Artisan Partners Limited Partnership’s holdings in Stevanato Group were worth $51,333,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the company. Van Berkom & Associates Inc. acquired a new stake in Stevanato Group in the fourth quarter worth about $39,000. PNC Financial Services Group Inc. raised its position in shares of Stevanato Group by 1,457.6% in the 4th quarter. PNC Financial Services Group Inc. now owns 5,654 shares of the company’s stock valued at $123,000 after purchasing an additional 5,291 shares during the last quarter. US Bancorp DE raised its position in shares of Stevanato Group by 17.9% in the 4th quarter. US Bancorp DE now owns 8,527 shares of the company’s stock valued at $186,000 after purchasing an additional 1,295 shares during the last quarter. Marco Investment Management LLC acquired a new stake in Stevanato Group in the 4th quarter worth approximately $203,000. Finally, Captrust Financial Advisors grew its position in Stevanato Group by 12.7% during the 3rd quarter. Captrust Financial Advisors now owns 13,100 shares of the company’s stock worth $262,000 after purchasing an additional 1,480 shares during the last quarter.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the stock. Bank of America lifted their price objective on shares of Stevanato Group from $24.00 to $26.00 and gave the stock a “buy” rating in a research note on Friday, December 13th. Wolfe Research assumed coverage on Stevanato Group in a research note on Friday, December 13th. They set an “outperform” rating and a $28.00 price target on the stock. UBS Group reduced their price objective on Stevanato Group from $24.00 to $23.50 and set a “neutral” rating for the company in a research note on Friday, March 7th. William Blair reaffirmed an “outperform” rating on shares of Stevanato Group in a report on Friday, March 7th. Finally, Morgan Stanley reiterated an “equal weight” rating and issued a $23.00 price target (down previously from $24.00) on shares of Stevanato Group in a report on Tuesday, December 3rd. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of €25.70 ($27.93).

Stevanato Group Stock Down 0.3 %

Shares of STVN opened at €20.25 ($22.01) on Friday. Stevanato Group S.p.A. has a 52 week low of €16.56 ($18.00) and a 52 week high of €32.98 ($35.85). The company has a quick ratio of 1.21, a current ratio of 1.81 and a debt-to-equity ratio of 0.22. The company has a market capitalization of $6.13 billion, a price-to-earnings ratio of 43.09, a PEG ratio of 7.18 and a beta of 0.60. The stock’s 50-day moving average price is €20.90 and its 200-day moving average price is €20.59.

Stevanato Group (NYSE:STVN) last announced its quarterly earnings results on Thursday, March 6th. The company reported €0.20 ($0.22) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of €0.20 ($0.22). The company had revenue of €352.68 million during the quarter, compared to the consensus estimate of €346.26 million. Stevanato Group had a return on equity of 9.86% and a net margin of 10.47%. On average, sell-side analysts predict that Stevanato Group S.p.A. will post 0.5 EPS for the current year.

Stevanato Group Company Profile

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.